Emergent BioSolutions Inc.
EBS
$11.60
$0.756.91%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 788.90M | 851.60M | 965.40M | 1.04B | 1.13B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 788.90M | 851.60M | 965.40M | 1.04B | 1.13B |
| Cost of Revenue | 404.00M | 434.60M | 674.60M | 731.40M | 822.60M |
| Gross Profit | 384.90M | 417.00M | 290.80M | 312.20M | 302.90M |
| SG&A Expenses | 185.70M | 223.30M | 256.60M | 288.70M | 317.40M |
| Depreciation & Amortization | 65.10M | 65.10M | 65.20M | 65.10M | 65.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 655.00M | 723.00M | 996.40M | 1.09B | 1.21B |
| Operating Income | 133.90M | 128.60M | -31.00M | -41.60M | -79.50M |
| Income Before Tax | 105.90M | 190.70M | -62.30M | -142.90M | -169.80M |
| Income Tax Expenses | 30.00M | 51.20M | 69.30M | 47.70M | 39.00M |
| Earnings from Continuing Operations | 75.90 | 139.50 | -131.60 | -190.60 | -208.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.90M | 139.50M | -131.60M | -190.60M | -208.80M |
| EBIT | 133.90M | 128.60M | -31.00M | -41.60M | -79.50M |
| EBITDA | 230.00M | 227.40M | 72.40M | 64.00M | 29.50M |
| EPS Basic | 1.41 | 2.61 | -2.55 | -3.63 | -4.00 |
| Normalized Basic EPS | 1.47 | 1.79 | -0.21 | -1.18 | -1.57 |
| EPS Diluted | 1.30 | 2.45 | -2.71 | -3.73 | -4.11 |
| Normalized Diluted EPS | 1.36 | 1.68 | -0.32 | -1.23 | -1.62 |
| Average Basic Shares Outstanding | 216.00M | 215.90M | 214.30M | 212.10M | 209.80M |
| Average Diluted Shares Outstanding | 222.20M | 221.30M | 219.70M | 214.60M | 212.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |